News - Novo Nordisk


Current filters:

Novo Nordisk

Popular Filters

80 to 104 of 131 results

Novo Nordisk invests $100 million for bigger R&D center in China


Denmark's Novo Nordisk (NOV: N) said this morning that it is investing an additional $100 million to…

Asia-PacificFinancialNovo NordiskPharmaceuticalResearch

Novo Nordisk insulin degludec passes first regulatory hurdle in Japan


Danish insulin giant Novo Nordisk (NOV: N) revealed on Friday that its ultra-long-acting insulin degludec…

Asia-PacificDegludecDiabetesNovo NordiskPharmaceuticalRegulation

Novo Nordisk ups forecast on strong diabetes drug sales


Denmark's Novo Nordisk, the world's largest insulin producer, this morning posted financial results for…

DiabetesFinancialNovo NordiskPharmaceuticalResearch

FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg


Denmark's Novo Nordisk (NOV: N), the world's largest insulin maker, says that the US Food and Drug Administration…

DiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk and AstraZeneca among firms to invest in Russian pharma hub


In Russia, the Kaluga government plans to establish a pharmaceutical manufacturing hub in the region…

AstraZenecaEuropeFinancialMarkets & MarketingMenariniNovo NordiskPharmaceuticalSTADA Arzneimittel

Novo Nordisk links with JDRF on type 1 diabetes R&D; type 2 study results


Danish insulin giant Novo Nordisk (NOV: N) is partnering with the US charitable organization JDRF to…

DiabetesHealthcareNovo NordiskPharmaceuticalResearch

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

US FDA delays approval of Novo Nordisk's ultra-long acting insulins


The US Food and Drug Administration has extended the regulatory review period for the ultra-long-acting…

DegludecDegludecPlusDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulation

FDA expands Levemir use to young children; negative on tafamidis


Denmark-based global insulin giant Novo Nordisk (NOV: N) says that the US Food and Drug Administration…

DiabetesLevemirNorth AmericaNovo NordiskPfizerPharmaceuticalRare diseasesRegulationtafamidisVyndaqel

Novo Nordisk to acquire Taiwanese osteo/RA technology


Danish insulin giant Novo Nordisk (NOV: N) has acquired rights to technology developed by a southern…

Anti-Arthritics/RheumaticsLicensingNovo NordiskPharmaceuticalResearch

Exec appointments at Novo Nordisk and Teva


Danish insulin giant Novo Nordisk (NOV: N) says that former Pfizer executive Robert Clark will be joining…

GenericsManagementNovo NordiskPharmaceuticalTeva Pharmaceutical Industries

New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit


The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund…

Asia-PacificDiabetesGlucaGenNovo NordiskNovoMixNovoSevenPharmaceuticalPricingRegulation

Novo Nordisk in-licenses drug delivery technology from Caisson


Danish insulin giant Novo Nordisk (NVO: N) has entered into a development and license agreement with…

Caisson BiotechHeparinexLicensingNovo NordiskPharmaceutical

Novo Nordisk starts year with 15% net profits hike


Danish insulin giant Novo Nordisk (NOV: N) reported first-quarter 2012 results last Friday, with a 13%…

DegludecDiabetesFinancialNovo NordiskPharmaceuticalRyzodegTresiba

Novo Nordisk collaborates with Oxford University on RA and other inflammatory diseases research


Departing from its core competence, diabetes, Danish insulin giant Novo Nordisk (NOV: N) and the Kennedy…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceuticalResearch

Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal


Danish diabetes specialist Novo Nordisk (NOV: N) says that its investigational ultra-long-acting insulin…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Ground-breaking on new Novo Nordisk plant in Russia


Danish insulin giant Novo Nordisk (NOV: N) broke ground yesterday on a new $100 million plant in Russia…

EuropeFinancialInsulinMarkets & MarketingNovo NordiskPharmaceutical

Novo Nordisk tests a new business model to improve insulin access in Kenya


As part of an official Danish state visit to Kenya, global insulin giant Novo Nordisk (NOV: N) last week…

DiabetesInsulinMarkets & MarketingNovo NordiskPharmaceuticalPricingRest of the World

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk


The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

FDA OKs pregnancy use of Novo Nordisk diabetes therapy Levemir


The US Food and Drug Administration has approved Levemir (insulin detemir [rDNA origin] injection), from…

DiabetesLevemirNorth AmericaNovo NordiskPharmaceuticalRegulation

Pfizer and Biocon cancel biosimilars deal


Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Victoza sales boost Novo Nordisk


Danish insulin giant Novo Nordisk (NVO: N) yesterday reported full-year 2011 sales of 66.35 billion Danish…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

80 to 104 of 131 results

Back to top